Radius Health Inc (RDUS) Given Average Recommendation of “Hold” by Brokerages

Shares of Radius Health Inc (NASDAQ:RDUS) have earned a consensus rating of “Hold” from the nine analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $40.80.

Several research analysts have issued reports on the company. Zacks Investment Research lowered Radius Health from a “hold” rating to a “sell” rating in a research note on Thursday, January 10th. ValuEngine upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, April 1st. BidaskClub upgraded Radius Health from a “hold” rating to a “buy” rating in a research note on Friday, April 5th. Finally, HC Wainwright assumed coverage on Radius Health in a research note on Thursday, February 14th. They set a “neutral” rating and a $22.00 price objective for the company.

Radius Health stock traded down $0.77 during mid-day trading on Monday, hitting $21.43. 991,897 shares of the company were exchanged, compared to its average volume of 595,264. The company has a debt-to-equity ratio of 2.97, a current ratio of 5.92 and a quick ratio of 5.79. Radius Health has a 1-year low of $12.81 and a 1-year high of $35.05. The firm has a market capitalization of $980.42 million, a P/E ratio of -4.39 and a beta of 0.95.

In other news, Director Debasish Roychowdhury sold 4,800 shares of the stock in a transaction on Thursday, April 11th. The stock was sold at an average price of $22.15, for a total transaction of $106,320.00. Following the sale, the director now owns 5,500 shares in the company, valued at $121,825. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jessica Hopfield bought 12,800 shares of the firm’s stock in a transaction dated Tuesday, March 5th. The shares were acquired at an average price of $19.23 per share, for a total transaction of $246,144.00. Following the acquisition, the director now directly owns 12,800 shares of the company’s stock, valued at approximately $246,144. The disclosure for this purchase can be found here. 3.42% of the stock is currently owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the company. BB Biotech AG grew its holdings in shares of Radius Health by 1.8% during the fourth quarter. BB Biotech AG now owns 6,710,276 shares of the biopharmaceutical company’s stock worth $110,652,000 after purchasing an additional 120,000 shares during the last quarter. HealthCor Management L.P. boosted its holdings in Radius Health by 77.0% in the third quarter. HealthCor Management L.P. now owns 3,584,580 shares of the biopharmaceutical company’s stock valued at $63,806,000 after acquiring an additional 1,559,580 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Radius Health by 1.5% in the third quarter. Vanguard Group Inc. now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after acquiring an additional 53,281 shares during the last quarter. Vanguard Group Inc boosted its holdings in Radius Health by 1.5% in the third quarter. Vanguard Group Inc now owns 3,571,571 shares of the biopharmaceutical company’s stock valued at $63,574,000 after acquiring an additional 53,281 shares during the last quarter. Finally, Eversept Partners LP boosted its holdings in Radius Health by 4.4% in the fourth quarter. Eversept Partners LP now owns 552,053 shares of the biopharmaceutical company’s stock valued at $9,103,000 after acquiring an additional 23,061 shares during the last quarter.

Radius Health Company Profile

Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.

Read More: Put Option

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.